ACADIA Pharmaceuticals Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: ACADIA Pharmaceuticals Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: SAN Diego
Headquarters state / province: California
Headquarters country: United States
Fiscal year end: December
Ticker symbol: ACAD
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001070494
EIN: 06-1376651
Wikidata ID: Q4671580

Board of directors

Follow this board

Adora Ndu · Director
Since 2023
Catherine E. Owen · Director · Chief Executive Officer
Since 2024
Daniel B. Soland · Director
Since 2023
Edmund Harrigan · Director
Since 2023
Elizabeth A. Garofalo · Director
Since 2023
Felix Baker · Director Overboarded
Since 2023
James M. Daly · Director
Since 2023
Jonathan Poole · Director
Since 2026
Julian Baker · Director Overboarded
Since 2023
Laura Brege · Director
Since 2023
Stephen Davis · Director · CEO
Since 2023

Chief executives

Catherine E. Owen · Chief Executive Officer

Since September 2024

100 CEO score

Outstanding · grade A+

Out of 100, from shareholder return, dividends, growth and acquisitions.

Partial: only 20% of the scoring weight is on file.

Revenue growth 20%: 100

20% of the scoring weight is on file. Figures cover December 2023 – December 2025.

Stephen Davis · CEO

Until September 2024 · Former

Director election results

Annual meeting of May 29, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Edmund Harrigan

85.4%

Board connections

9 of this board's directors also sit on 23 other boards. 23 are in the same sector.

Shared director Other board Same sector +7 more in the list below

DBV Technologies S.A. Same sector
via Adora Ndu, Daniel B. Soland, Felix Baker and Julian Baker
Incyte Corp. Same sector
via Edmund Harrigan, Felix Baker and Julian Baker
Madrigal Pharmaceuticals Inc. Same sector
via Felix Baker, James M. Daly and Julian Baker
BeOne Medicines Ltd. Same sector
via Felix Baker and Julian Baker
Bicycle Therapeutics plc Same sector
via Felix Baker and Julian Baker
Denali Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
Immunocore Holdings plc Same sector
via Felix Baker and Julian Baker
Kiniksa Pharmaceuticals International plc Same sector
via Felix Baker and Julian Baker
Kodiak Sciences Inc Same sector
via Felix Baker and Julian Baker
Kymera Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
Neurogene Inc. Same sector
via Felix Baker and Julian Baker
Prelude Therapeutics Incorporated Same sector
via Felix Baker and Julian Baker
Replimune Group Inc. Same sector
via Felix Baker and Julian Baker
TScan Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
vTv Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
Agios Pharmaceuticals Inc. Same sector
via Catherine E. Owen
Alector Inc. Same sector
via Elizabeth A. Garofalo
Cytokinetics Incorporated Same sector
via James M. Daly
Edgewise Therapeutics Inc. Same sector
via Laura Brege
Halozyme Therapeutics Inc. Same sector
via James M. Daly
Mirum Pharmaceuticals Inc. Same sector
via Laura Brege
Pacira BioSciences Inc. Same sector
via Laura Brege
Xenon Pharmaceuticals Inc. Same sector
via Elizabeth A. Garofalo

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $2,799,523; 24 sales by 5 insiders

Date	Insider	Transaction	Shares	Price	Value
Oct 30, 2026	Schneyer Mark C. Officer (EVP, CHIEF FINANCIAL OFFICER)	Open-market sale	−3,321	$20.88	$69,342
Oct 15, 2026	Schneyer Mark C. Officer (EVP, CHIEF FINANCIAL OFFICER)	Grant or award	+6,815	—	—
Aug 6, 2026	Schneyer Mark C. Officer (EVP, CHIEF FINANCIAL OFFICER)	Option exercise	+14,292	$17.84	$254,969
Aug 6, 2026	Schneyer Mark C. Officer (EVP, CHIEF FINANCIAL OFFICER)	Open-market sale	−5,000	$29.00	$145,000
Aug 6, 2026	Schneyer Mark C. Officer (EVP, CHIEF FINANCIAL OFFICER)	Open-market sale	−9,292	$29.34	$272,627
Aug 5, 2026	Schneyer Mark C. Officer (EVP, CHIEF FINANCIAL OFFICER)	Option exercise	+5,849	$17.84	$104,346
Aug 5, 2026	Schneyer Mark C. Officer (EVP, CHIEF FINANCIAL OFFICER)	Open-market sale	−5,849	$29.00	$169,621
Jul 30, 2026	Thompson Elizabeth H.Z. Officer (EVP, Head of Research & Dev)	Open-market sale	−16,508	$26.13	$431,354
Jul 30, 2026	Thompson Elizabeth H.Z. Officer (EVP, Head of Research & Dev)	Open-market sale	−50	$26.17	$1,309
Jul 29, 2026	Thompson Elizabeth H.Z. Officer (EVP, Head of Research & Dev)	Option exercise	+32,272	—	—
Jun 26, 2026	Kihara James Officer (PRINCIPAL ACCOUNTING OFFICER)	Open-market sale	−11,421	$26.08	$297,860
May 29, 2026	Baker Brothers Life Sciences LP Director, 10% owner	Grant or award	+18,622	—	—
May 29, 2026	Edmund Harrigan Director	Option exercise	+8,107	—	—
May 29, 2026	Adora Ndu Director	Option exercise	+8,107	—	—
May 29, 2026	Laura Brege Director	Option exercise	+8,107	—	—

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization ALX Oncology Holdings Inc. Nasdaq: ALXO · South SAN Francisco, United States Organization

Questions about ACADIA Pharmaceuticals Inc.

Who is the CEO of ACADIA Pharmaceuticals Inc.?

Catherine E. Owen has been ACADIA Pharmaceuticals Inc.'s Chief Executive Officer since September 2024.

How many directors are on ACADIA Pharmaceuticals Inc.'s board?

ACADIA Pharmaceuticals Inc.'s board has 11 directors: Adora Ndu, Catherine E. Owen, Daniel B. Soland, Edmund Harrigan, Elizabeth A. Garofalo, Felix Baker, James M. Daly, Jonathan Poole, Julian Baker, Laura Brege and 1 other.

Are ACADIA Pharmaceuticals Inc. insiders buying or selling shares?

Over the last 12 months, ACADIA Pharmaceuticals Inc. insiders made no open-market purchases and sold $2.8 million of shares in 24 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is ACADIA Pharmaceuticals Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="acadia-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.